BR112018009879A2 - biomarcador da doença renal policística e seus usos - Google Patents

biomarcador da doença renal policística e seus usos

Info

Publication number
BR112018009879A2
BR112018009879A2 BR112018009879A BR112018009879A BR112018009879A2 BR 112018009879 A2 BR112018009879 A2 BR 112018009879A2 BR 112018009879 A BR112018009879 A BR 112018009879A BR 112018009879 A BR112018009879 A BR 112018009879A BR 112018009879 A2 BR112018009879 A2 BR 112018009879A2
Authority
BR
Brazil
Prior art keywords
pkd
patient
kidney disease
polycystic kidney
biomarker
Prior art date
Application number
BR112018009879A
Other languages
English (en)
Inventor
Bukanov Nikolai
Moreno Sarah
E Weeden Timothy
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112018009879A2 publication Critical patent/BR112018009879A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

são aqui fornecidos métodos para determinar a eficácia do tratamento da doença renal policística (pkd) em um paciente, diagnosticar a pkd em um paciente, graduar a pkd em um paciente e monitorar a pkd em um paciente. esses métodos incluem determinar um único ou múltiplos níveis de ambp. também são fornecidos kits que incluem um anticorpo que se liga especificamente à proteína ambp e pelo menos um anticorpo que se liga especificamente a um marcador adicional de pkd.
BR112018009879A 2015-11-18 2016-11-15 biomarcador da doença renal policística e seus usos BR112018009879A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257089P 2015-11-18 2015-11-18
PCT/US2016/062075 WO2017087409A1 (en) 2015-11-18 2016-11-15 Biomarker of polycystic kidney disease and uses thereof

Publications (1)

Publication Number Publication Date
BR112018009879A2 true BR112018009879A2 (pt) 2018-11-13

Family

ID=57539614

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009879A BR112018009879A2 (pt) 2015-11-18 2016-11-15 biomarcador da doença renal policística e seus usos

Country Status (12)

Country Link
US (2) US11116755B2 (pt)
EP (1) EP3377908B1 (pt)
JP (1) JP6895963B2 (pt)
KR (1) KR20180083902A (pt)
CN (1) CN108700594B (pt)
AU (1) AU2016357720A1 (pt)
BR (1) BR112018009879A2 (pt)
CO (1) CO2018006126A2 (pt)
EA (1) EA201891170A1 (pt)
MX (1) MX2018006250A (pt)
WO (1) WO2017087409A1 (pt)
ZA (1) ZA201803035B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023145898A1 (ja) * 2022-01-27 2023-08-03 国立大学法人新潟大学 慢性腎臓病の尿検査方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710227B1 (en) 1998-09-16 2004-03-23 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
US6703395B2 (en) 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US20040006074A1 (en) 1998-04-28 2004-01-08 The Government Of The United States Of America Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
CA2256121A1 (en) 1998-06-08 1999-12-08 Hong Wang Cyclin-dependent kinase inhibitors as plant growth regulators
ATE318818T1 (de) 1998-06-16 2006-03-15 Us Gov Health & Human Serv Annellierte azepinone als inhibitoren cyclin- abhängiger kinasen
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
AU781094B2 (en) 1999-05-24 2005-05-05 Avi Biopharma, Inc. Antisense to c-myc for treatment of polycystic kidney disease
US6593356B2 (en) 1999-10-20 2003-07-15 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
JP2004507455A (ja) 2000-04-25 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途
AU2001287157A1 (en) 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
CA2432417A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
GB0101686D0 (en) 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
WO2003063764A2 (en) 2001-07-10 2003-08-07 Bristol-Myers Squibb Pharma Company 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
EP1545533A1 (en) 2002-09-04 2005-06-29 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2006501260A (ja) 2002-09-04 2006-01-12 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7067661B2 (en) 2002-09-04 2006-06-27 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA05002570A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
MY136840A (en) 2002-09-19 2008-11-28 Schering Corp Pyrazolopyridines as cyclin dependent kinase inhibitors
US6992080B2 (en) 2002-09-19 2006-01-31 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
PE20050081A1 (es) 2002-09-23 2005-03-01 Schering Corp Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
US7576085B2 (en) 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
CA2499874A1 (en) 2002-09-23 2004-04-01 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
JP2008507540A (ja) 2004-07-21 2008-03-13 チューレン ユニバーシティ ヘルス サイエンス センター Ｐａｃａｐ化合物を用いる腎臓機能障害及び多発性骨髄腫の治療
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
EP2167485B1 (en) 2007-05-31 2015-09-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US20100184110A1 (en) 2007-06-06 2010-07-22 Siemens Healthcare Diagnostics Inc. Predictive diagnostics for kidney disease
EP2320886B1 (en) 2008-07-28 2017-06-28 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN102271678B (zh) 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
US20120077263A1 (en) 2009-06-05 2012-03-29 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
CN102018702B (zh) 2009-09-16 2012-07-18 北京大学 银杏内酯b的一种用途
SG10201407881WA (en) 2009-11-27 2015-01-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
WO2011084548A2 (en) 2009-12-15 2011-07-14 King Faisal Specialist Hospital & Research Centre Methods and compositions for detecting recesssive familial fsgs and uses thereof
EP2622095B1 (en) 2010-10-01 2016-09-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the progression and treating a chronic kidney disease in a patient
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
US20130225443A1 (en) 2010-11-05 2013-08-29 Kyoto University Method of examining polycystic kidney disease and method of screening for therapeutic agent of the disease
WO2013052505A2 (en) 2011-10-03 2013-04-11 Celmatix, Inc. Methods and devices for assessing risk to a putative offspring of developing a condition
WO2013059119A1 (en) 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN102590491B (zh) 2012-02-06 2014-12-10 中国人民解放军第三军医大学第一附属医院 一种用于早期筛查或辅助诊断泌尿系统疾病的检测试剂盒、检测方法及其用途
EP2869824B1 (en) 2012-07-03 2024-03-27 Fondazione Centro San Raffaele 2-deoxyglucose for use in the treatment of autosomal dominant polycystic kidney disease or polycystic liver disease
JOP20130273B1 (ar) * 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
US10871495B2 (en) 2014-08-04 2020-12-22 Genzyme Corporation Biomarkers of polycystic kidney disease and uses thereof

Also Published As

Publication number Publication date
ZA201803035B (en) 2019-02-27
EA201891170A1 (ru) 2018-11-30
MX2018006250A (es) 2018-09-05
WO2017087409A1 (en) 2017-05-26
KR20180083902A (ko) 2018-07-23
CO2018006126A2 (es) 2018-07-10
JP2019502902A (ja) 2019-01-31
US11116755B2 (en) 2021-09-14
JP6895963B2 (ja) 2021-06-30
CN108700594B (zh) 2021-06-29
US20180338961A1 (en) 2018-11-29
AU2016357720A1 (en) 2018-07-05
US20210379031A1 (en) 2021-12-09
EP3377908A1 (en) 2018-09-26
EP3377908B1 (en) 2020-08-05
CN108700594A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
BR112014031365A2 (pt) métodos de detectar doenças ou condições
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
BR112014018970A8 (pt) Dispositivos de coleta de amostra com agentes de estabilização sanguínea
BR112016029521A2 (pt) ?kit, dispositivo e método para a detecção de câncer de estômago?
BR112018008799A2 (pt) método de prognóstico
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112019005172A2 (pt) método e kit para analisar uma amostra
CO2019002607A2 (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
CO2019006234A2 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal
BR112019006862A2 (pt) dispositivo de análise e método para testagem de uma amostra
BR112018069316A2 (pt) métodos para detectar presença de pelo menos uma espécie de bordetella patogênica e selecionar um paciente que exibe sintomas semelhantes à coqueluche, e, kit para detectar presença de pelo menos uma espécie de bordetella patogênica.
BR112018003147A2 (pt) anticorpos e testes para detecção de cd37
CL2019003485A1 (es) Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)
BR112017021507A2 (pt) métodos para a seleção de inibidores seletivos e não seletivos de fosfatase
BR112018009879A2 (pt) biomarcador da doença renal policística e seus usos
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
BR112017024196A2 (pt) ?biomarcadores para uma terapia de combinação compreendendo lenvatinib e everolimus?
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации
CO2017001596A2 (es) Biomarcadores de enfermedad poliquística renal y usos de los mismos
BR112018071395A2 (pt) métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso
UA118158U (uk) Спосіб діагностики первинного системного некротизивного васкуліту
BR112017012553A2 (pt) método de tratamento de um paciente que sofre de um câncer, método para o diagnóstico de um câncer, método para o prognóstico de um paciente que sofre de câncer, método para determinar se um paciente com um câncer e método para otimizar a eficácia terapêutica de uma terapia anticâncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]